Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments
Gliomas are one of the most lethal types of cancers accounting for ∼80% of all central nervous system (CNS) primary malignancies. Among gliomas, glioblastomas (GBM) are the most aggressive, characterized by a median patient survival of fewer than 15 months. Recent molecular characterization studies...
Autors principals: | Mahmoud S. Alghamri, Brandon L. McClellan, Carson S. Hartlage, Santiago Haase, Syed Mohd Faisal, Rohit Thalla, Ali Dabaja, Kaushik Banerjee, Stephen V. Carney, Anzar A. Mujeeb, Michael R. Olin, James J. Moon, Anna Schwendeman, Pedro R. Lowenstein, Maria G. Castro |
---|---|
Format: | Article |
Idioma: | English |
Publicat: |
Frontiers Media S.A.
2021-05-01
|
Col·lecció: | Frontiers in Pharmacology |
Matèries: | |
Accés en línia: | https://www.frontiersin.org/articles/10.3389/fphar.2021.680021/full |
Ítems similars
-
Murine brain tumor microenvironment immunophenotyping using mass cytometry
per: Brandon L. McClellan, et al.
Publicat: (2022-06-01) -
Impact of epigenetic reprogramming on antitumor immune responses in glioma
per: Brandon L. McClellan, et al.
Publicat: (2023-01-01) -
Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies
per: Maria B. Garcia-Fabiani, et al.
Publicat: (2021-06-01) -
Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment
per: Andrea Franson, et al.
Publicat: (2022-09-01) -
H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models
per: Santiago Haase, et al.
Publicat: (2022-11-01)